Feasibility study: Watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression

Journal of Urology

Volumn 167, Issue 4 I, 2002, Pages 1664-1669

  Choo, Richard ^a   Klotz, Laurence ^a   Danjoux, Cyril ^a   Morton, Gerard C ^a   Deboer, Gerrit ^a   Szumacher, Ewa ^a   Fleshner, Neil ^a   Bunting, Peter ^a   Hruby, George ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Biopsy; Disease progression; Prostate; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; DISEASE COURSE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT CANCER; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE DISEASE;

EID: 0036130518     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-5347(05)65174-9     Document Type: Article

References (19)

1. A decision analysis of alternative treatment strategies for clinically localized prostate cancer
2. A structured literature review of treatment for localized prostate cancer
3. Expectant management of early stage prostatic cancer: Swedish experience
4. Population-based study of long-term survival in patients with clinically localised prostate cancer
5. Proceedings: Etiology, epidemiology, and pathology of prostatic cancer
6. Latent prostatic cancer in a consecutive autopsy series
7. Natural history of changes in prostate specific antigen in early stage prostate cancer
8. Nonparametric estimation from incomplete observations
9. The national duration of cancer
10. Results of conservative management of clinically localized prostate cancer
11. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators
12. Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma
13. Prostate specific antigen velocity as a measure of the natural history of prostate cancer: Defining a 'rapid riser' subset
14. Observations of prostate specific antigen doubling time in Japanese patients with nonmetastatic prostate carcinoma
15. Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy
16. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume
17. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients
18. Observations of pretreatment prostate-specific antigen doubling time in 107 patients referred for definitive radiotherapy